Literature DB >> 25337633

A case of severe Ebola virus infection complicated by gram-negative septicemia.

Benno Kreuels1, Dominic Wichmann, Petra Emmerich, Jonas Schmidt-Chanasit, Geraldine de Heer, Stefan Kluge, Abdourahmane Sow, Thomas Renné, Stephan Günther, Ansgar W Lohse, Marylyn M Addo, Stefan Schmiedel.   

Abstract

Ebola virus disease (EVD) developed in a patient who contracted the disease in Sierra Leone and was airlifted to an isolation facility in Hamburg, Germany, for treatment. During the course of the illness, he had numerous complications, including septicemia, respiratory failure, and encephalopathy. Intensive supportive treatment consisting of high-volume fluid resuscitation (approximately 10 liters per day in the first 72 hours), broad-spectrum antibiotic therapy, and ventilatory support resulted in full recovery without the use of experimental therapies. Discharge was delayed owing to the detection of viral RNA in urine (day 30) and sweat (at the last assessment on day 40) by means of polymerase-chain-reaction (PCR) assay, but the last positive culture was identified in plasma on day 14 and in urine on day 26. This case shows the challenges in the management of EVD and suggests that even severe EVD can be treated effectively with routine intensive care.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25337633     DOI: 10.1056/NEJMoa1411677

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  103 in total

1.  [Intensive care treatment of a patient with Ebola virus disease in Germany].

Authors:  D Wichmann; B Kreuels; S Schmiedel; S Kluge
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-02-17       Impact factor: 0.840

2.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

Review 3.  Ebola virus disease.

Authors:  Nicholas J Beeching; Manuel Fenech; Catherine F Houlihan
Journal:  BMJ       Date:  2014-12-10

4.  Isolation in patients with Ebola virus disease.

Authors:  Dominic Wichmann; Stefan Schmiedel; Stefan Kluge
Journal:  Intensive Care Med       Date:  2014-12-11       Impact factor: 17.440

5.  Ebola care and research protocols.

Authors:  Anders Perner; Robert A Fowler; Rinaldo Bellomo; Ian Roberts
Journal:  Intensive Care Med       Date:  2014-11-27       Impact factor: 17.440

Review 6.  Insights from clinical research completed during the west Africa Ebola virus disease epidemic.

Authors:  Amanda Rojek; Peter Horby; Jake Dunning
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

7.  Impact of Intravenous Fluid Therapy on Survival Among Patients With Ebola Virus Disease: An International Multisite Retrospective Cohort Study.

Authors:  Adam R Aluisio; Derrick Yam; Jillian L Peters; Daniel K Cho; Shiromi M Perera; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Michael A Smit; Tao Liu; Adam C Levine
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

8.  Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit.

Authors:  P S C Rees; L E M Lamb; T C Nicholson-Roberts; C N Ardley; M S Bailey; D E Hinsley; T E Fletcher; S J Dickson
Journal:  Intensive Care Med       Date:  2015-03-12       Impact factor: 17.440

9.  Preparedness for admission of patients with suspected Ebola virus disease in European hospitals: a survey, August-September 2014.

Authors:  M D de Jong; C Reusken; P Horby; M Koopmans; M Bonten; Jd Chiche; C Giaquinto; T Welte; F Leus; J Schotsman; H Goossens
Journal:  Euro Surveill       Date:  2014-12-04

Review 10.  Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease.

Authors:  Katharine Ker; Gavin Tansley; Deirdre Beecher; Anders Perner; Haleema Shakur; Tim Harris; Ian Roberts
Journal:  Cochrane Database Syst Rev       Date:  2015-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.